Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction

Gene Therapy

Volumn 10, Issue 9, 2003, Pages 725-732

  Johnson, K J ^a   Peng, K W ^a   Allen, C ^a   Russell, S J ^a   Galanis, E ^a  

^a MAYO CLINIC   (United States)

Author keywords

FMG; GALV; Gliomas; MMP; Targeting

Indexed keywords

1,10 PHENANTHROLINE; BLOOD CLOTTING FACTOR 10A; CD40 LIGAND; FUSOGENIC MEMBRANE GLYCOPROTEIN; GELATINASE A; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; N HYDROXYPIPERAZINECARBOXAMIDE; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CELL DEATH; CELL FUSION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; ENZYME SUBSTRATE; FIBROBLAST; GENE ACTIVATION; GENE CONSTRUCT; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GIBBON LEUKEMIA VIRUS; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; SYNCYTIUM; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ZYMOGRAPHY;

ANIMALS; ARTIFICIAL GENE FUSION; CELL DEATH; ENZYME INHIBITORS; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GLIOMA; HUMANS; LEUKEMIA VIRUS, GIBBON APE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PHENANTHROLINES; PIPERAZINES; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL ENVELOPE PROTEINS;

ALOCASIA MACRORRHIZOS; GIBBON APE LEUKEMIA VIRUS; HYLOBATES SP.;

EID: 0038780760     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301951     Document Type: Article

References (27)

1. Galanis E et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther 2001; 12: 811-821.
2. Bateman A et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 2000; 60: 1492-1497.
3. Higuchi H et al. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy Cancer Res 2000; 60: 6396-6402.
4. Diaz RM et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther 2000; 7: 1656-1663.
5. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295-305.
6. Olah Z et al. The cellular receptor for Gibbon ape leukemia virus is a novel high affinity phosphate transporter. J Biol Chem 1994; 269: 25426-25431.
7. Forestell SP et al. Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer. Gene Ther 1994; 4: 600-610.
8. Morling FJ, Peng KW, Cosset F-L, Russel SJ. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 1997; 234: 51-61.
9. Peng K-W, Vile RG, Cosset F-L, Russell SJ. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 1999; 6: 1552-1557.
10. Hotary K et al. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000; 149: 1309-1323.
11. Nakada M et al. Expression and tissue localization of membrane-type 1 2 and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999; 154: 417-428.
12. Lampert K et al. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 1998; 153: 429-437.
13. Apodaca G et al. Expression of metalloproteinases, and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990; 50: 2322-2329.
14. Yamamoto M et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996; 56: 384-392.
15. Ye Q-Z, Johnson LL, Yu AE, Hope D. Reconstructed 19 kDa catalytic domain of gelatinase A is an active proteinase. Biochemistry 1995; 34: 4702-4708.
16. Will H et al. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autocatalytic activation. J Biol Chem 1996; 271: 17119-17123.
17. Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and flurogenic substrates. Methods Enzymol 1981; 80: 341-361.
18. Uhm JH, Dooley NP, Villemure JG, Yong VW. Glioma invasion in vitro: regulation by matrix metalloprotease-2 and protein kinase C. Clin Exp Metastasis 1996; 14: 421-433.
19. Rodriguez GC et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-β. Gynecol Oncol 2001; 80: 245-253.
20. Peng K-W et al. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 1997; 8: 729-738.
21. Fielding AK et al. A hyperfusogenic Gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 2000; 6: 817-826.
22. Buchholz CJ et al. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol 1998; 16: 951-954.
23. Stetler-Stevenson WG et al. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-573.
24. Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci 1999; 880: 288-307.
25. Moser TL et al. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994; 56: 552-559.
26. Hewitt RE et al. Distribution of collagenase and tissue inhibitor of metalloproteases (TIMP) in colorectal tumors. Int J Cancer 1991; 49: 666-672.
27. Ueno H et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997; 57: 2055-2060.